$ESTA

Establishment Labs Holdings Inc (ESTA) Shares Fall 5.2% -- What

Establishment Labs Holdings Inc (ESTA) shares fell 5.2% to $58.45 on October 13, 2026, continuing a 19.8% year-to-date decline. The stock is undervalued by 10.5% according to GF Value™, with a GF Score™ of 76/100. Insiders sold $36.9M in shares over the past year, while some gurus increased their positions. The company shows strong growth but weak financial strength and profitability.

Original reporting
Published Oct 13, 2026, 10:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 11:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$ESTA
Bearish
medium confidence
Mentioned
$ESTA
Relevance
4/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$ESTABearishLow
01

Why it matters

The price decline and insider activity suggest short‑term bearish pressure, but valuation gap may present a contrarian entry point.

02

Market read

The article reports a notable price drop and insider selling, offering limited trading insight beyond existing market sentiment.

03

What to watch

Potential upcoming product launches or contract wins not yet disclosed could mitigate the downside.

Relevance 4/10Novelty 2/10Timing: after‑market close on Oct 13

Background

Establishment Labs Holdings (ESTA) is a U.S.-listed cosmetic device maker with recent volatility and insider sell‑off.

Company-level read

Ticker impact

$ESTABearishMedium confidence
Context

Shares fell 5.2% to $58.45 on Oct 13, 2026, extending a 19.8% YTD decline.

Expected impact

likely further downside as market prices in weak financial strength and continued insider sell‑off

Evidence & confidence

Insider sales of $36.9M and a 5% intraday decline suggest bearish sentiment; no new catalyst to reverse the trend.

Market effects

Limited; the cosmetic/beauty sector may see modest pressure if other peers face similar valuation concerns.

U.S. small‑cap market could see slight drag from the stock's decline.

Low; the story is company‑specific with no broader macro implications.

Counterpoint

The 10% valuation discount could attract value‑oriented buyers despite weak fundamentals.

Key entities

  • Establishment Labs Holdings Inc

    U.S. listed cosmetic device manufacturer (ticker: ESTA).

Related articles

$ESTAMed

Establishment Labs Q2 Earnings Call Highlights

Establishment Labs (NASDAQ:ESTA) reported Q2 updates on its Motiva breast implant business. Outside the U.S. revenue rose 4.4% to $42.8M, with Europe up 16%. Its Minimally Invasive platform generated $12.1M revenue, nearing 15% of full-year global revenue. Gross margin improved to 70.6%. Cash was $71.2M. FDA site audits began for U.S. reconstruction; no material revenue expected until 2027.

$ESTAMed

Establishment Labs® Reports Second Quarter 2026 Financial Results

ESTABLISHMENT LABS HOLDINGS INC. (ESTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Malavika William mwilliam@establishmentlabs.com Establishment Labs ® Reports Second Quarter 2026 Financial Results NEW YORK, NY, August 6, 2026 -- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology compa

Foreign Investors Dump $8.4 Billion in Korean Chip Stocks; Samsung, SK Hynix Post Biggest Weekly Plunge Since Global Financial Crisis

Foreign investors sold $8.4B in Korean chip stocks, with Samsung (005930.KS) and SK Hynix (000660.KS) falling 17.8% and 24.3% respectively, their worst weekly declines since 2008. The sell-off was driven by AI bubble concerns, semiconductor cycle fears, and Chinese competition. Analysts are divided on whether the drop is an overcorrection or signals further downside.

$TSLAMed

Tesla Roadster Hovers Over Five Cars, But Shares Fall 2%

Tesla showcased a hovering Roadster using SpaceX rocket tech, sparking merger speculation. Analysts like Garrett Nelson (CFRA) raised Tesla's price target to $475, citing a 90% merger probability. Despite enthusiasm, shares fell 2.13% to $354.72, as skeptics questioned the tech's commercial viability.